Improvement of refractory cognitive impairment following anifrolumab treatment in a patient with systemic lupus erythematosus
Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, has been approved for the treatment of systemic lupus erythematosus (SLE). However, its role in cognitive impairment remains unclear. A woman in her early 70s was diagnosed with SLE based on the presence of pancytopenia, proteinuria, hypocomplementemia, and elevated serum anti-double-stranded DNA antibody levels. Treatment was initiated with oral prednisolone at 50 mg/day and intravenous cyclophosphamide at 500 mg. Cognitive dysfunction persisted despite improvements in systemic manifestations, with a decreased Mini-Mental State Examination (MMSE) score and abnormalities on the clock drawing test (CDT). Results from brain magnetic resonance imaging were unremarkable. Cerebrospinal fluid analysis showed mildly elevated interleukin-6 levels, but negative results for anti-ribosomal P antibodies. Although delirium was initially considered among the differential diagnoses, the patient did not meet the criteria for delirium. Cognitive impairment associated with SLE disease activity was therefore suspected. A second infusion of cyclophosphamide was administered, but cognitive impairment exacerbated. Intravenous infusion of anifrolumab was subsequently initiated, after which cognitive function improved over several days, with increasing MMSE score and normalization of CDT performance. No relapse of SLE was seen with anifrolumab every four weeks combined with hydroxychloroquine, and prednisolone was tapered to 4 mg/day by 11 months after treatment initiation. Although the relative contributions of neuropsychiatric involvement and excessive type I interferon activity to cognitive impairment remain uncertain, this case raises the possibility that anifrolumab may have contributed to the improvement of cognitive impairment.
Authors
- Shunichiro Hanai (ORCID: https://orcid.org/0000-0001-8964-8513)
- Daiki Nakagomi (ORCID: https://orcid.org/0000-0003-1682-9799)
- Mayu Yazaki (ORCID: https://orcid.org/0009-0002-0780-9868)
- Nakako Tanaka‐Mabuchi (ORCID: https://orcid.org/0009-0005-3929-4215)
- Sunao Kubota (ORCID: https://orcid.org/0009-0004-8746-3901)
- Kojiro Ikeda (ORCID: https://orcid.org/0009-0001-2356-7101)
Institutions
- University of Yamanashi Hospital (JP)
- University of Yamanashi (JP)
Publication Details
- Journal
- Modern Rheumatology Case Reports
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1093/mrcr/rxag115
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00